Santen Pharmaceutical
Manufacturing · Japan · 3,744 Employees
View Company Info for Free
About
Headquarters
Grand Front Osaka Tower A 4-20 Ofuka-cho, Kita-...Phone Number
+81 676648621Website
www.santen.comRevenue
$2.1 BillionStock Symbol
SNPHFIndustry
Most Recent Scoops
Who is Santen Pharmaceutical
Santen Pharmaceutical Org Chart
Is Santen Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Santen Pharmaceutical launches new products
Funding: Get notified immidiatlly once Santen Pharmaceutical has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Santen Pharmaceutical
Check out if Santen Pharmaceutical is spiking on competitors!
Earning: See what the market has to say on Santen Pharmaceutical recently announced quarterly report
Santen Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Santen Pharmaceutical had a recent Job posting/layoffs
Check if Santen Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Santen Pharmaceutical as Masked Content
Find 2 more new buyers
Santen Pharmaceutical Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Santen Pharmaceutical Tech Stack
A closer look at the technologies used by Santen Pharmaceutical
Most Recent Scoops
Santen Pharmaceutical News & Media
Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye and Ocular Allergy
TORONTO--(BUSINESS WIRE)--Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada. Cationorm® Plus is a unique hydrating artificial tear that restores moisture in the eye to provide long-lasting relief for dry eye and ocular allergy symptoms. Dry eye occurs when there is a problem with the tear film that normally keeps the eyes moist and lubricated.1,2,3 Symptoms of dry eye include redness, burning, stinging,Santen and UBE Received FDA Approval for OMLONTI® (Omidenepag Isopropyl Ophthalmic Solution) 0.002% for the Reduction of Elevated Intraocular Pressure in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
EMERYVILLE, Calif. & UBE, Japan--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the U.S. Food and Drug Administration (FDA) has approved OMLONTI® (omidenepag isopropyl ophthalmic solution) 0.002% eye drops for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. OMLONTI® is developed jointly by SanSanten’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for the Treatment of Vernal Keratoconjunctivitis in Children and Adults in the United States
EMERYVILLE, Calif.--(BUSINESS WIRE)--Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is now available in the United States for the treatment of vernal keratoconjunctivitis (VKC), a rare and recurrent allergic eye condition that causes severe inflammation of the surface of the eye. Verkazia – which is administered as an eye drop – isAerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopressa®/Rhokiinsa® (netarsudil ophthalmic solution) 0.02% and Rocklatan®/Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. The expanded collaboration includes Europe, Commonwealth of Independent States (CIS) countries, China, India, parts of Latin America and the Oceania countri
Frequently Asked Questions Regarding Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as... Read More